In contrast, another study found no significant difference in the immune response to HER2 when a HER2 peptide-pulsed DC vaccine was administered either intratumorally, intranodally, or intratumorally plus intranodally in 54 patients with HER2-positive breast cancer [54]. Here, ERBB2 is linked to breast carcinoma.